May. 1 at 1:54 PM
$ALHC Today's drop is a gift. Make sure to unwrapped it. Tripled my position in ALHC :) Supppppper bullish!
ALHC is dropping today despite strong Q1 results. The move looks more like a sell-the-news / valuation reset than a clear fundamental disappointment.
Main reasons:
The stock had already run hard into earnings.
Investor’s Business Daily noted ALHC’s Relative Strength Rating recently jumped into the 80+ range and that the stock was forming a later-stage base near a potential breakout area. That means expectations were already elevated before results.
Q1 results were strong, but maybe not enough for the valuation.
Alignment reported Q1 revenue of
$1.24B, up 33.3% year over year, Medicare Advantage membership up 30.9%, and adjusted EBITDA up 87.6%. Those are good numbers, but the stock was priced for a lot of good news already.
Guidance was raised, but investors may have wanted a bigger raise.
The company raised the midpoint of guidance for membership, revenue, adjusted gross profit, and adjusted EBITDA. Full-year 2026 revenue guidance is now
$5.16B–
$5.205B, with adjusted EBITDA of
$138M–
$163M. Positive, but the market may have expected an even stronger outlook after the recent stock move.
Medicare Advantage stocks carry regulatory/reimbursement risk.
Alignment is a Medicare Advantage company. The company itself flags risks around MA funding, Star Ratings, regulations, care-provider relationships, medical costs, and government approvals. These risks can weigh on the whole group even when company-specific results look good.
Technical reversal matters.
ALHC opened around
$20.73, traded as high as
$22.53, then fell near
$18.87, down about 16% intraday. That type of move suggests traders initially reacted positively, then sellers took control quickly.
Bottom line:
The drop does not appear to be because Q1 was bad. Q1 was actually strong. The likely issue is that ALHC had become a crowded momentum trade, and investors are taking profits or reassessing valuation after earnings. For the stock to stabilize, I’d watch whether it can reclaim the
$20–
$21 area and whether analysts raise estimates after the call.
